We then used single cell RNA-sequencing (scRNAseq) of circulating immune cells from a clinical trial cohort of melanoma patients treated with immune checkpoint inhibitors (ICI) to explore the potential relationship between LAG-3-expressing cells and clinical outcomes. The gene discussed is LAG3; the disease is melanoma.